OBSESSIVE-COMPULSIVE ADOLESCENTS AND THEIR PARENTS: A PSYCHOMETRIC STUDY

The present study examined obsessive personality traits and achievement expectations of parents with an obsessive-compulsive adolescent. The Leyton Obsessional Inventory (LOI) and rating scales of occupational and educational aspirations and expectations were administered to both parents and the adolescent of 12 families with an obsessional adolescent and 10 families having an anxious, nonobsessional son or daughter. The parents' LOI scores were similar in the two groups, though higher than normal adults on the trait and resistance scales. The obsessional adolescents perceived their parents to hold significantly higher career demands for them than the anxious adolescents.     

La tomografía por emisión de positrones (pet) y pet-tac en riñón,vías urinarias y próstata: actualización

PET has demonstrated its utility in management decisions in several types of tumors. In urologic tract tumors and prostate cancer its diagnostic performance has been lower due to the urinary excretion of the radiotracer, which can mask the presence of lesions. However, specific protocols must be applied that improve the diagnostic performance of PET with 18FFDG in the evaluation of pelvic lesions. Furthermore, prostate cancer is a low-grade tumor with low avidity for 18F-FDG. In spite of these limitations, with PET new and interesting possibilities have been presented. The availability of PET-CT systems has improved its diagnostic performance. On the other hand, the development of new radiotracers that allow targeting other molecular processes and that are metabolized by pathways different to the urinary tract signifies an important advantage compared to 18F-FDG and has evidenced interesting results.     

GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility

Abstract There is an urgent clinical need for a safe, efficacious stimulant of gastric emptying; current therapies include erythromycin (an antibiotic with additional properties which preclude chronic use) and metoclopramide (a 5‐hydroxytryptamine type 4 receptor agonist and an antagonist at brain D₂ receptors, associated with movement disorders). To move away from the complex motilide structure of erythromycin, a small molecule motilin receptor agonist, GSK962040, was identified and characterized. The compound was evaluated using recombinant human receptors, rabbit and human isolated stomach preparations known to respond to motilin and in vivo, by measuring its ability to increase defecation in conscious rabbits. At the human motilin receptor, the pEC₅₀ (the negative logarithm to base 10 of the EC₅₀ value, the concentration of agonist that produces 50% of the maximal response) values for GSK962040 and erythromycin as agonists were, respectively, 7.9 and 7.3; GSK962040 had no significant activity at a range of other receptors (including ghrelin), ion channels and enzymes. In rabbit gastric antrum, GSK962040 300 nmol L^?1–10 μmol L^?1 caused a prolonged facilitation of the amplitude of cholinergically mediated contractions, to a maximum of 248 ± 47% at 3 μmol L^?1. In human‐isolated stomach, GSK962040 10 μmol L^?1, erythromycin 10 μmol L^?1 and [Nle¹³]‐motilin 100 nmol L^?1, each caused muscle contraction of similar amplitude. In conscious rabbits, intravenous doses of 5 mg kg^?1 GSK962040 or 10 mg kg^?1 erythromycin significantly increased faecal output over a 2‐h period. Together, these data show that GSK962040, a non‐motilide structure, selectively activates the motilin receptor. Simplification of the structural requirements to activate this receptor greatly facilitates the design of potentially new medicines for gastroparesis.